Shire Aims For Four Launches By Year-End
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm plans to introduce the ADHD therapy NRP104 in the fourth quarter.
You may also be interested in...
Two Amgen EPO Patent Infringement Claims Upheld By Federal Appeals Court
In a mixed decision, the appeals court also reversed a lower court's decision that rival drug makers had infringed a different patent.
Two Amgen EPO Patent Infringement Claims Upheld By Federal Appeals Court
In a mixed decision, the appeals court also reversed a lower court's decision that rival drug makers had infringed a different patent.
Shire/Noven Daytrana "Approvable" Pending Data Clarification
FDA letter for the ADHD patch also requests additional information on post-marketing surveillance and post-marketing studies, the companies say.